1. Academic Validation
  2. Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers

Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers

  • CNS Drug Rev. 2006 Spring;12(1):39-52. doi: 10.1111/j.1527-3458.2006.00039.x.
M N Romanelli 1 N Galeotti C Ghelardini D Manetti E Martini F Gualtieri
Affiliations

Affiliation

  • 1 Dipartimento di Scienze Farmaceutiche, University of Florence, Sesto Fiorentino, Italy. novella.romanelli@unifi.it
Abstract

DM232 (unifiram) and DM235 (sunifiram) are potent cognition-enhancers, which are four order of magnitude more potent than piracetam. These compounds, although not showing affinity in binding studies for the most important central receptors or channels, are able to prevent amnesia induced by modulation of several neurotransmission systems. These compounds are able to increase the release of acetylcholine from rat cerebral cortex, and, as far as unifiram is concerned, to increase the amplitude of fEPSP in rat hippocampal slices. In vitro experiments, performed on hippocampal slices, also supported the hypothesis of a role of the AMPA receptors for the cognition-enhancing properties of unifiram and sunifiram.

Figures
Products